

Literatura:

1. Augustin M, Reich K, Glaeske G et al.: Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany. *Acta Derm Venereol* 2010; 90(2): 147–151.
2. Brembilla NC, Senra L, Boehncke WH: The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond. *Front Immunol* 2018; 9: 1682. doi: 10.3389/fimmu.2018.01682.
3. Cohen AD, Dreiher J, Birkenfeld S: Psoriasis associated with ulcerative colitis and Crohn´s disease. *J Eur Acad Dermatol Venerol* 2009; 23: 561–565.

4. Colombel JF, Sandborn WJ, Ghosh S et al.: Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3. *Am J Gastroenterol* 2014; 109(11): 1771-1780.
5. Gasslitter I, Kirsten N, Augustin M et al.: Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study. *Arch Dermatol Research* 2019. <https://doi.org/10.1007/s00403-019-01907-y>.
6. Gelfand JM, Troxel AB, Lewis JD et al.: The risk of mortality in patients with psoriasis: results from a population based study. *Arch Dermatol* 2007; 143: 1493-1499.
7. Gold R, Kappos L, Arnold DL et al.: Placebo - controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. *N Engl J Med* 2012; 367: 1098-1107.
8. Gordon KB, Blauvelt A, Papp KA et al.; UNCOVER-1 Study Group; UNCOVER-2 Study Group; UNCOVER-3 Study Group. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. *N Engl J Med* 2016; 375(4): 345-356.
9. Gottlieb AB, Kalb RE, Langley RG et al.: Safety observations in 12 095 patients with psoriasis enrolled in an international registry (PSOLAR): Experience with infliximab and other systemic and biologic therapies. *J Drugs Dermatol* 2014; 13: 1441-1448.
10. Kimmel G, Chima M, Kim HJ et al.: Brodalumab in the treatment of moderate to severe psoriasis in patients when previous antiinterleukin 17A therapies have failed. *J Am Acad Dermatol* 2019; 81(3): 857-859.
11. Lomicová I, Suchý D, Pizinger K, Cetkovská P: A case of lupus-like syndrome in a patient receiving adalimumab and a brief review of the literature on drug-induced lupus erythematosus. *J Clin Pharm Ther* 2017. doi: 10.1111/jcpt.12506.
12. Meissner M, Valesky EM, Kippenberger S, Kaufmann R: Dimethyl fumarate - only an anti-psoriatic medication? *J Dtsch Dermatol Ges* 2012; 10: 793-801.
13. Millán-Pasucal J, Turpin-Fenoll L, Del Saz-Saucedo P et al.: Psoriasis during natalizumab treatment of multiple sclerosis. *J Neurol* 2012; 259: 2758-2760.
14. Nast A, Gisondi P, Ormerod AD et al.: European S3 - Guidelines on the systemic treatment of psoriasis vulgaris - Update 2015 - Short version - EDF incooperation with EADV and IPC. *J Eur Acad Dermatol Venerol* 2015; 29: 2277-2294.
15. Ogdie A, Weiss P: The Epidemiology of Psoriatic Arthritis. *Rheum Dis Clin North Am* 2015; 41: 545-568.
16. Perez-Alvarez R, Pérez-de-Lis M, Ramos-Casals M; BIOGEAS study group. Biologics-induced autoimmune diseases. *Curr Opin Rheumatol* 2013; 25: 56-64.
17. Reddy SP, Martires K, Wu JJ: The risk of melanoma and hematologic cancers in patients with psoriasis. *J Am Acad Dermatol* 2017; 76: 639-647.
18. Saurat J, Stingl G, Dubertret L et al.: Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). *Br J Dermatol* 2007; 558-566.

19. van Lumig PP, Driessen RJ, Berends MA et al.: Safety of treatment with biologics for psoriasis in daily practice: 5 year data. *J Europ Acad Dermatol Venereol* 2012; 26: 283–291.
20. van Vollenhoven RF, Hahn BH, Tsokos GC et al.: Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. *Lancet* 2018; 392(10155): 1330–1339.
21. Venturini M, Zanca A, Venturuzzo A et al.: Secukinumab for patients with plaque psoriasis affected by multiple sclerosis. A mini-review with a representative case report. *J Eur Acad Dermatol Venereol* 2019. doi: 10.1111/jdv.16035. [Epub ahead of print.]

Next chapters will be discussing common clinical presentations with individual chapters on psoriasis and psoriatic arthritis. The last years a significant progress can be seen in the therapy of psoriasis. This is the main reason why this book will include as much as more actual information concerning local and systemic treatment, including biologic therapy. In order to prepare the book as practical as possible for the reader, case reports with interesting patients will be included. Book will be directed not only to dermatologists but also to physicians with other specialties, mainly general practitioners who see daily patients treated with biologic therapy.

DMARDs	biologické nebo biosimilární choroby modifikující léky
BSA	procento povrchu těla
CASPAR	Classification Criteria for Psoriatic Arthritis
CD	Crohnova nemoc
CMP	celní mozkové příboby
COPD	chronická obstrukční plicní choroba
CRP	C-reaktivní protein
CsA	cyklosporin A
csDMARDs	konvenční syntetické choroby modifikující léky
CT	počítačová tomografie
CDS IEP	Česká dermatovenerologická společnost
CEFS	Česká pneumologická a fizeologická společnost
CRS	Česká reumatologická společnost
DAPSA	Disease Activity Index for Psoriatic Arthritis
DRE	léky indukovaný lupus erythematosus
DIP	distální intersticiální nefropatie
DLQI	dermatologický dotazník kvality života
dsDNA	dvouvláknová kyselina deoxyribonukleová
FGF	foli growth factor
FSH	folikostimulační hormon
ESR	sedimentace erytrocytů
GK	glukokortikoidy